A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes
Authors
Keywords
Diabetic nephropathy, Drug development, Liver steatosis, Metabolic syndrome, Soluble epoxide hydrolase
Journal
DIABETOLOGIA
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-07-21
DOI
10.1007/s00125-018-4685-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus
- (2017) Yoshio Sumida et al. HEPATOLOGY RESEARCH
- Emerging therapeutics for the treatment of diabetic nephropathy
- (2016) Jehrod Brenneman et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
- (2016) Zobair M. Younossi et al. HEPATOLOGY
- Perirenal Fat Promotes Renal Arterial Endothelial Dysfunction in Obese Swine through Tumor Necrosis Factor-α
- (2016) Shuangtao Ma et al. JOURNAL OF UROLOGY
- NAFLD and diabetes mellitus
- (2016) Herbert Tilg et al. Nature Reviews Gastroenterology & Hepatology
- Soluble epoxide hydrolase: A potential target for metabolic diseases
- (2016) Jinlong He et al. Journal of Diabetes
- Effect of n-3 PUFA supplementation at different EPA:DHA ratios on the spontaneously hypertensive obese rat model of the metabolic syndrome
- (2015) Eunice Molinar-Toribio et al. BRITISH JOURNAL OF NUTRITION
- PPARγ Regulation in Hypertension and Metabolic Syndrome
- (2015) Madeliene Stump et al. CURRENT HYPERTENSION REPORTS
- Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
- (2015) Robert J. Wong et al. GASTROENTEROLOGY
- N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators
- (2015) René Blöcher et al. JOURNAL OF MEDICINAL CHEMISTRY
- Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice
- (2015) Clothilde Roche et al. PROSTAGLANDINS & OTHER LIPID MEDIATORS
- Inhibition of soluble epoxide hydrolase attenuates hepatic fibrosis and endoplasmic reticulum stress induced by carbon tetrachloride in mice
- (2015) Todd R. Harris et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Azilsartan Decreases Renal and Cardiovascular Injury in the Spontaneously Hypertensive Obese Rat
- (2014) Md. Abdul Hye Khan et al. CARDIOVASCULAR DRUGS AND THERAPY
- Thiazolidinediones and the Promise of Insulin Sensitization in Type 2 Diabetes
- (2014) Raymond E. Soccio et al. Cell Metabolism
- Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition
- (2014) Md. Abdul Hye Khan et al. CLINICAL SCIENCE
- Diabetic Kidney Disease: A Report From an ADA Consensus Conference
- (2014) Katherine R. Tuttle et al. DIABETES CARE
- Ramipril-Induced Liver Injury: Case Report and Review of the Literature
- (2013) Antonios Douros et al. AMERICAN JOURNAL OF HYPERTENSION
- The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988-2010
- (2013) S. Stark Casagrande et al. DIABETES CARE
- Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats
- (2013) John D Imig et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Epoxyeicosatrienoic Acids (EETs) Regulate Epithelial Sodium Channel Activity by Extracellular Signal-regulated Kinase 1/2 (ERK1/2)-mediated Phosphorylation
- (2013) Nataliya Pidkovka et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes
- (2012) Guifen Qiang et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Inhibition of Soluble Epoxide Hydrolase Attenuates High-Fat-Diet–Induced Hepatic Steatosis by Reduced Systemic Inflammatory Status in Mice
- (2012) Yan Liu et al. PLoS One
- Pharmacological Inhibition of Soluble Epoxide Hydrolase Ameliorates Diet-Induced Metabolic Syndrome in Rats
- (2011) Abishek Iyer et al. Experimental Diabetes Research
- Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States
- (2011) Ian H. de Boer JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Up-Regulation of PPAR-γ mRNA Expression in the Liver of Obese Patients: an Additional Reinforcing Lipogenic Mechanism to SREBP-1c Induction
- (2011) Paulina Pettinelli et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats
- (2011) Victor P Bilan et al. JOURNAL OF ENDOCRINOLOGY
- Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy
- (2011) Daniel Batlle et al. KIDNEY INTERNATIONAL
- Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance
- (2011) A. Luria et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pioglitazone: side effect and safety profile
- (2010) Priya Shah et al. Expert Opinion On Drug Safety
- Targeting Epoxides for Organ Damage in Hypertension
- (2010) John D Imig JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Oxidative stress in early diabetic nephropathy: fueling the fire
- (2010) Dhruv K. Singh et al. Nature Reviews Endocrinology
- Inhibition of Soluble Epoxide Hydrolase Attenuated Atherosclerosis, Abdominal Aortic Aneurysm Formation, and Dyslipidemia
- (2009) Le-Ning Zhang et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The Metabolic Syndrome
- (2009) Matthew V. Potenza et al. NUTRITION IN CLINICAL PRACTICE
- Potential for peroxisome proliferator-activated receptor-?? agonists in progression: beyond metabolism
- (2008) Agnes B Fogo CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- PPAR-γ agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-β
- (2008) Toru Kawai et al. LABORATORY INVESTIGATION
- Effects of Weight Loss on Nonalcoholic Fatty Liver Disease
- (2008) Nila Rafiq et al. SEMINARS IN LIVER DISEASE
- The pathogenesis of diabetic nephropathy
- (2008) Suma Dronavalli et al. Nature clinical practice. Endocrinology & metabolism
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now